Please assess the completion status of the following clinical trial:

Trial Title: Ivermectin for Post Exposure Prophylaxis of Covid-19

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Asymptomatic individuals exposed to a confirmed positive COVID-19 case within 5 days from the study recruitment day (include household, workplace and social close contact)~2. Aged ≥18 years; male or female~3. No fever with temperature less than 37.5ºC~4. RTK Ag for COVID-19 is negative on the recruitment day.~5. For subject who had received COVID-19 vaccination:~   * Any primary series vaccine (eg: Pfizer, Sinovac, AstraZeneca etc) : past 90 days after the second dose~  * Any booster vaccine: past 90 days after the booster dose~6. In women of childbearing potential (18-55 years old), negative pregnancy test and agree to use any contraceptive method up to 7 days after the second dose of IP administration~7. Have access to video and phone call~8. Willing to take 2 doses of study medication (2 days apart between Dose 1 and Dose 2)~9. Willing to comply with all study procedures~10. Able to provide written informed consent~Exclusion Criteria:~1. Unable to take drugs by mouth~2. History of positive confirmed COVID-19 infection within past 3 months~3. Involved in any COVID-19 vaccine clinical trial~4. Patients with suspected concomitant bacterial, fungal infections, concurrent congestive heart failure prior to initiation of study drug~5. Known case of liver disease (any severity)~6. Alcohol intake more than recommended (2 drinks or more in a day for men and 1 drink or more in a day for women)~7. Mal-absorption syndrome or other clinically significant gastrointestinal disease that may affect absorption of the study drug (non-correctable vomiting, diarrhea, ulcerative colitis, and others).~8. Pregnant or nursing/breastfeeding women or women planning for pregnancy.~9. Female patients who cannot consent to contraceptive use (any method) from the start of IP administration to 7 days after the second dose of IP administration~10. Male patients whose partner cannot agree to use the contraception method as in 9)~11. Patients with a history of gout or on treatment for gout or hyperuricemia~12. Patients receiving immunosuppressant~13. Patients who have previously received Ivermectin.~14. Patients who are not able to provide written consent.~15. Other patients judged ineligible by the principal investigator or sub-investigator

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Treatment group: (Type: ACTIVE_COMPARATOR): Ivermectin 0.4 mg/kg/day (maximum 24 mg)
- Control group (Type: PLACEBO_COMPARATOR): Placebo-inactive substance

Based on this trial design, predict the completion outcome and termination type (if applicable).